Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.

World journal of urology - 1 Aug 2017

Deng Chuangzhong, Chen Jieping, Guo Shengjie, Wang Yanjun, Zhou Qianghua, Li Zaishang, Yang Xingping, Yu Xingsu, Zhang Zhenfeng, Zhou Fangjian, Han Hui, Yao Kai

Abstract excerpt

PURPOSE: The aberrant expression of casein kinase 2 (CK2) has been reported to be involved in the tumorigenesis and progression of prostate cancer. The inhibition of CK2 activity represses androgen-dependent prostate cancer cells by attenuating the androgen receptor (AR) signaling pathway. In this study, we examined the effect of CK2 inhibition in castration-resistant prostate cancer (CRPC) cells, in which AR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Anilides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Casein Kinase II

Share to Naphthyridines

Share to NF-kappa B p50 Subunit

Share to Phenazines

Share to Prostatic Neoplasms, Castration-Resistant

Share to Tumor Stem Cell Assay

Source

Identifiers

PMID: 28105499
DOI: 10.1007/s00345-016-1996-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.PMID 28105499Read ↗

Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.Semantic proximity Read ↗

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.Semantic proximity Read ↗

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity Read ↗

CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.Semantic proximity Read ↗

Targeting CDK9: a promising therapeutic opportunity in prostate cancerSemantic proximity Read ↗

The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistanceSemantic proximity Read ↗

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerSemantic proximity Read ↗

Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7Semantic proximity Read ↗

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.Semantic proximity Read ↗

MicroRNA‑149 inhibits cancer cell malignant phenotype by regulating Akt1 in C4‑2 CRPC cell line.Semantic proximity Read ↗

Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.Semantic proximity Read ↗

Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration‐resistant prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.